Abatacept (CTLA4Ig), a selective T-cell costimulation modulator, has been approved for the treatment of psoriatic arthritis patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs, but not for those with uncontrolled skin lesions, nor with axial involvement. In this review, we will try to interpret such a differential efficacy of abatacept on the psoriatic arthritis clinical domains, on the basis of its differential effectiveness on the diverse T-cell subsets at different sites. Clinical and biological profiles of abatacept possible responders will be provided.
Zizzo, G., Gremese, E., Ferraccioli, G., Abatacept in the treatment of psoriatic arthritis: biological and clinical profiles (of the responders)., <<IMMUNOTHERAPY>>, 2018; (N/A): N/A-N/A. [doi:10.2217/imt-2018-0014] [http://hdl.handle.net/10807/122406]
Abatacept in the treatment of psoriatic arthritis: biological and clinical profiles (of the responders).
Zizzo, GaetanoPrimo
;Gremese, ElisaSecondo
;Ferraccioli, Gianfranco
Ultimo
2018
Abstract
Abatacept (CTLA4Ig), a selective T-cell costimulation modulator, has been approved for the treatment of psoriatic arthritis patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs, but not for those with uncontrolled skin lesions, nor with axial involvement. In this review, we will try to interpret such a differential efficacy of abatacept on the psoriatic arthritis clinical domains, on the basis of its differential effectiveness on the diverse T-cell subsets at different sites. Clinical and biological profiles of abatacept possible responders will be provided.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
